Tags

Type your tag names separated by a space and hit enter

MASTL: A novel therapeutic target for Cancer Malignancy.
Cancer Med. 2020 Jul 21 [Online ahead of print]CM

Abstract

Targeting mitotic kinases is an emerging anticancer approach with promising preclinical outcomes. Microtubule-associated serine/threonine kinase like (MASTL), also known as Greatwall (Gwl), is an important mitotic kinase that regulates mitotic progression of normal or transformed cells by blocking the activity of tumor suppressor protein phosphatase 2A (PP2A). MASTL upregulation has now been detected in multiple cancer types and associated with aggressive clinicopathological features. Apart, an aberrant MASTL activity has been implicated in oncogenic transformation through the development of chromosomal instability and alteration of key oncogenic signaling pathways. In this regard, recent publications have revealed potential role of MASTL in the regulation of AKT/mTOR and Wnt/β-catenin signaling pathways, which may be independent of its regulation of PP2A-B55 (PP2A holoenzyme containing a B55-family regulatory subunit). Taken together, MASTL kinase has emerged as a novel target for cancer therapeutics, and hence development of small molecule inhibitors of MASTL may significantly improve the clinical outcomes of cancer patients. In this article, we review the role of MASTL in cancer progression and the current gaps in this knowledge. We also discuss potential efficacy of MASTL expression for cancer diagnosis and therapy.

Authors+Show Affiliations

VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32692487

Citation

Fatima, Iram, et al. "MASTL: a Novel Therapeutic Target for Cancer Malignancy." Cancer Medicine, 2020.
Fatima I, Singh AB, Dhawan P. MASTL: A novel therapeutic target for Cancer Malignancy. Cancer Med. 2020.
Fatima, I., Singh, A. B., & Dhawan, P. (2020). MASTL: A novel therapeutic target for Cancer Malignancy. Cancer Medicine. https://doi.org/10.1002/cam4.3141
Fatima I, Singh AB, Dhawan P. MASTL: a Novel Therapeutic Target for Cancer Malignancy. Cancer Med. 2020 Jul 21; PubMed PMID: 32692487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MASTL: A novel therapeutic target for Cancer Malignancy. AU - Fatima,Iram, AU - Singh,Amar B, AU - Dhawan,Punita, Y1 - 2020/07/21/ PY - 2019/11/27/received PY - 2020/04/09/revised PY - 2020/04/22/accepted PY - 2020/7/22/entrez PY - 2020/7/22/pubmed PY - 2020/7/22/medline KW - CANCER KW - CELL cycle KW - MASTL KW - chemoresistance JF - Cancer medicine JO - Cancer Med N2 - Targeting mitotic kinases is an emerging anticancer approach with promising preclinical outcomes. Microtubule-associated serine/threonine kinase like (MASTL), also known as Greatwall (Gwl), is an important mitotic kinase that regulates mitotic progression of normal or transformed cells by blocking the activity of tumor suppressor protein phosphatase 2A (PP2A). MASTL upregulation has now been detected in multiple cancer types and associated with aggressive clinicopathological features. Apart, an aberrant MASTL activity has been implicated in oncogenic transformation through the development of chromosomal instability and alteration of key oncogenic signaling pathways. In this regard, recent publications have revealed potential role of MASTL in the regulation of AKT/mTOR and Wnt/β-catenin signaling pathways, which may be independent of its regulation of PP2A-B55 (PP2A holoenzyme containing a B55-family regulatory subunit). Taken together, MASTL kinase has emerged as a novel target for cancer therapeutics, and hence development of small molecule inhibitors of MASTL may significantly improve the clinical outcomes of cancer patients. In this article, we review the role of MASTL in cancer progression and the current gaps in this knowledge. We also discuss potential efficacy of MASTL expression for cancer diagnosis and therapy. SN - 2045-7634 UR - https://www.unboundmedicine.com/medline/citation/32692487/MASTL:_A_novel_therapeutic_target_for_Cancer_Malignancy_ L2 - https://doi.org/10.1002/cam4.3141 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.